Identifying best methods for the detection of subtle cognitive decline
Identifying best methods for the detection of subtle cognitive decline
批准号:
10328956
负责人:
Kelsey R Thomas
金额:
$15.8万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-15 至 2023-12-31
关键词:
Alzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer’s disease biomarkerAmyloidApplications GrantsArchivesAreaAttentionBiological MarkersClassificationClinicalClinical TrialsCognitiveCost SavingsDataData SetDementiaDiagnosisDiseaseEarly DiagnosisEarly InterventionEarly identificationFamilyFutureGoldHippocampus (Brain)Impaired cognitionIndividualLong-Term CareMeasuresMedicalMemoryMethodsNerve DegenerationNeuropsychologyOutcome MeasureParticipantPathogenesisPathologicPathologic ProcessesPatient Self-ReportPatientsPerformancePersonsPhasePositron-Emission TomographyPredictive ValuePreventionQuestionnairesReportingResearchResearch PersonnelResearch Project GrantsRiskSavingsScoring MethodTestingWhite Matter HyperintensityWorkaccurate diagnosisbasecare costsclassification algorithmclinical carecognitive changecognitive performancecostcost efficientdepressive symptomsdesigndetection methodexperiencefunctional declinefunctional disabilityimprovedinformantmild cognitive impairmentneuroimagingnext generationopen sourcepre-clinicalprognostic valueprogramsprogression markerprospectiverecruitrural areascreeningstatisticstau Proteinstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT
New submission for PAS-19-391 (Small Research Grant Program for the Next Generation of Researchers in
AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses [R03]).
Recent statistics show that if everyone alive in 2018 who will develop Alzheimer’s disease (AD) had early
and accurate diagnosis, there would be a savings of $7.9 trillion in medical and long-term care costs. Although
the advent of Alzheimer’s disease (AD) biomarkers has revolutionized our understanding of AD pathogenesis
during the preclinical phase, these approaches are often expensive, invasive, inaccessible due to rural location,
cost, or medical contraindications. Additionally, beyond a focus on AD biomarkers alone, it is essential to
emphasize that cognitive difficulties and subsequent functional impairment are the features of the disease that
negatively impact the lives of patients and their families. Emerging evidence suggests that subtle cognitive
changes may develop much earlier than originally described in models of AD and these subtle cognitive changes
add meaningful prognostic value, above and beyond AD biomarkers, in predicting progression to mild cognitive
impairment (MCI) and dementia. The gold standard approach for identifying subtle cognitive decline in preclinical
AD, however, remains unclear. Therefore, we propose to apply four different classification algorithms for subtle
cognitive decline in the open source Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. The four
classifications methods include two subjective approaches: self-reported subjective cognitive decline (Self-SCD)
and informant-reported subjective cognitive decline (Inform-SCD); and two objective approaches: a sensitive
neuropsychological individual test-based approach called objectively-defined subtle cognitive decline (Obj-SCD)
and a composite score-based approach using the preclinical Alzheimer’s cognitive composite to identify subtle
cognitive decline (PACC-SCD). The specific aims of this proposal include: 1) Compare AD biomarkers across 4
subtle cognitive decline definitions (Self-SCD, Inform-SCD, Obj-SCD, and PACC-SCD); 2) Determine which
subtle cognitive decline definitions best capture objective cognitive decline in the year preceding the subtle
cognitive decline classification; and 3) Examine longitudinal a) clinical and b) biomarker progression across
subtle cognitive decline definitions to determine the definitions with the best predictive utility. Results of the
proposed aims will likely impact the design of future studies, as having simple, yet reliable, and highly cost-
efficient methods for narrowing the initial pool of participants so that only those at greatest risk require a PET
scan for screening purposes would result in significant cost-savings. Additionally, these results will serve as
critical preliminary data for future grant applications, and be a key step toward improving clinically meaningful
early detection methods of those at risk for future decline, particularly those with limited access to AD biomarker
testing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heterogeneity of subtle cognitive decline phenotypes in community-dwelling older adults
-
批准号:10713843
-
项目类别:
-
资助金额:$183.82万
-
财政年份:2023
-
负责人:Kelsey R Thomas
-
依托单位:
Impact of Diabetes on Cognitive and Perfusion Inefficiencies in Preclinical AD
-
批准号:10578663
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Kelsey R Thomas
-
依托单位:
Impact of Diabetes on Cognitive and Perfusion Inefficiencies in Preclinical AD
-
批准号:10041705
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Kelsey R Thomas
-
依托单位:
Impact of Diabetes on Cognitive and Perfusion Inefficiencies in Preclinical AD
-
批准号:9777480
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Kelsey R Thomas
-
依托单位:
Impact of Diabetes on Cognitive and Perfusion Inefficiencies in Preclinical AD
-
批准号:10295163
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Kelsey R Thomas
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: